한글목차

세계의 면역조직화학 시장 규모는 2024년에 23억 8,000만 달러로 평가되었고, 2030년에는 35억 6,000만 달러에 달할 것으로 예측되며, CAGR은 6.90%를 나타낼 전망입니다.

세계의 면역조직화학 시장은 기술 혁신, 소비자 중심의 의료 수요 증가, 만성 질환 발병률 증가, 예방 치료에 대한 관심 증가와 같은 주요 촉진요인에 힘입어 상당한 성장을 거듭하고 있습니다. 혈액 검사부터 임신 키트, 혈당 모니터, 알레르기 테스트 솔루션에 이르기까지 면역조직화학 제품은 점차 개인이 스스로 건강을 관리하는 데 필수적인 도구로 자리 잡고 있습니다.

진단 기술의 발전, 소비자 건강 의식의 고조, 보다 저렴하고 접근 가능하며 개인화된 건강 솔루션으로의 전환에 힘입어 견고하게 유지되고 있습니다. 이러한 면역조직화학 제품이 건강 관리 전략의 중심이 되어감에 따라 시장은 계속 확대될 것으로 예상됩니다. 규제 지원과 진단 분야의 지속적인 혁신은 시장의 잠재력을 더욱 강화하여 면역조직화학 부문을 의료 및 진단 산업의 이해관계자들에게 수익성 높은 기회로 자리매김하고 있습니다.

시장 성장 촉진요인

만성 및 전염병 발생률 증가

주요 시장 과제

높은 기기 및 시약 비용

주요 시장 동향

디지털 병리학 및 인공지능(AI)과 IHC의 통합

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 목소리

제5장 세계의 면역조직화학 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율 및 예측
  • 제품 유형별(항체, 기기, 시약, 키트)
  • 용도별(진단, 암, 감염증, 심혈관 질환, 자가면역 질환, 당뇨병, 신장질환, 연구)
  • 최종 사용자별(병원, 진단 실험실, 연구 기관, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 면역조직화학 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 면역조직화학 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 유럽 : 국가별 분석
  • 독일
  • 영국
  • 이탈리아
  • 프랑스
  • 스페인

제8장 아시아태평양의 면역조직화학시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 남미의 면역조직화학 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 면역조직화학 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향 및 발전

• 최근 동향
• 제품 출시
• 합병 및 인수

제13장 세계의 면역조직화학 시장 : SWOT 분석

제14장 경쟁 구도

• Thermo Fisher Scientific Inc
• F. Hoffmann-La Roche Ltd.
• Merck KGaA
• Danaher Corporation
• PerkinElmer US LLC
• Bio-Rad Laboratories, Inc.
• Cell Signaling Technology, Inc.
• Bio SB
• Agilent Technologies, Inc.
• Abcam Limited

제15장 전략적 제안

제16장 기업 소개와 면책사항

영문목차

Global Immunohistochemistry market was valued at USD 2.38 Billion in 2024 and is expected to reach USD 3.56 Billion by 2030 with a CAGR of 6.90%. The global Immunohistochemistry market is undergoing substantial growth, fueled by key drivers such as technological innovation, increasing demand for consumer-driven healthcare, the rising incidence of chronic diseases, and a growing focus on preventive care. Immunohistochemistry products ranging from blood tests and pregnancy kits to glucose monitors and allergy testing solutions are progressively becoming integral tools for individuals managing their own health. These devices enable users to monitor a variety of health parameters independently, eliminating the need for clinical visits and empowering consumers to take control of their health.

The market's growth trajectory remains robust, underpinned by advancements in diagnostic technologies, heightened consumer health consciousness, and a shift toward more affordable, accessible, and personalized health solutions. As these Immunohistochemistry products become increasingly central to health management strategies, the market is expected to continue expanding. Regulatory support and ongoing innovations in diagnostics further enhance the market's potential, positioning the Immunohistochemistry segment as a lucrative opportunity for stakeholders in the healthcare and diagnostics industries.

Key Market Drivers

Rising Incidence of Chronic and Infectious Diseases

The global surge in chronic and infectious diseases has become one of the most significant demand drivers for the Immunohistochemistry (IHC) market. This trend is not only reshaping diagnostic approaches but also creating sustained growth opportunities for IHC-related products and services across healthcare systems worldwide. Chronic diseases represent the primary driver of global mortality and long-term disability, exerting substantial pressure on healthcare systems and economies. In 2020, these conditions such as cancer, cardiovascular disease, and diabetes were responsible for or contributed to 79% of all deaths worldwide. This figure is expected to rise to 84% by 2030, underscoring the urgent need for advanced diagnostic and therapeutic solutions, particularly in high-burden regions and aging populations. As the prevalence of chronic diseases particularly cancer, cardiovascular disorders, diabetes, and autoimmune conditions continues to rise globally, the need for precise, tissue-based diagnostic techniques has become critical. Immunohistochemistry, which allows for the detection of specific antigens in cells of a tissue section using labeled antibodies, is widely regarded as a gold-standard diagnostic tool, particularly in oncology. The technique aids in tumor classification, grading, and staging, directly influencing treatment decisions. In oncology, IHC is essential in detecting biomarkers such as HER2, Ki-67, and PD-L1, which guide targeted therapy. In autoimmune diseases, IHC helps identify inflammatory markers and immune cell infiltration patterns.

Malaria continues to pose a critical public health challenge, with approximately 249 million cases and over 608,000 deaths reported annually, disproportionately affecting children under the age of five in sub-Saharan Africa. Dengue presents an equally pressing concern, placing over 3.9 billion people globally at risk. The disease leads to millions of infections and thousands of fatalities each year, particularly in densely populated urban regions across Asia and Latin America. With the re-emergence and evolution of infectious diseases (e.g., tuberculosis, HIV, hepatitis, and most recently, COVID-19), there is growing interest in applying IHC techniques to pathogen detection and tissue-based immune response analysis. IHC is particularly useful in understanding the histopathological impact of viruses and bacteria on human tissues, which plays a crucial role in research and case-specific diagnosis, especially in post-mortem and advanced-stage analyses. This has been further amplified by the COVID-19 pandemic, which increased awareness of tissue-based diagnostic tools to study viral impact at the cellular level, thereby expanding the IHC use case beyond traditional cancer diagnostics. The World Health Organization (WHO) projects that non-communicable diseases (NCDs) will account for nearly 75% of all deaths by 2030. This projection is influencing both public and private healthcare institutions to adopt early and accurate diagnostic frameworks, where IHC plays a vital role. Simultaneously, growing healthcare spending especially in emerging economies is increasing access to sophisticated diagnostic platforms.

Key Market Challenges

High Cost of Instruments and Reagents

Despite the growing demand for immunohistochemistry in clinical diagnostics and pharmaceutical research, the high capital and operational costs associated with IHC instruments and reagents remain a significant barrier to market expansion, particularly in low- and middle-income countries (LMICs). Advanced IHC systems-including automated slide stainers, image analyzers, and digital pathology platforms require substantial upfront investment.

Recurrent costs of high-quality primary and secondary antibodies, detection kits, and substrate reagents are also high, especially for multiplexed or customized panels. Smaller pathology labs and diagnostic centers in emerging markets often lack the budget or funding mechanisms to acquire and maintain these systems, limiting the adoption of IHC technology. This cost barrier not only restricts market penetration in cost-sensitive regions but also slows down lab modernization in under-resourced healthcare systems.

Key Market Trends

Integration of Digital Pathology and Artificial Intelligence (AI) with IHC

The convergence of immunohistochemistry with digital pathology and AI-driven image analysis is redefining how tissue diagnostics are performed and interpreted. This trend is not only enhancing diagnostic accuracy but also improving scalability, standardization, and workflow efficiency. Digital slide scanners now allow high-resolution imaging of IHC-stained tissue, enabling remote diagnosis, archiving, and secondary consultations. AI algorithms are being developed to automatically quantify biomarker expression, such as HER2 or PD-L1, minimizing subjectivity and variability in interpretation.

AI-assisted platforms are accelerating the turnaround time for high-volume labs and facilitating telepathology, especially in resource-constrained or rural areas. This trend is transforming IHC from a manual, pathologist-driven technique to a more automated, data-driven process, making it attractive to both clinical and research sectors and opening up opportunities for scalable global adoption.

Key Market Players

• Thermo Fisher Scientific Inc
• F. Hoffmann-La Roche Ltd.
• Merck KGaA
• Danaher Corporation
• PerkinElmer U.S. LLC
• Bio-Rad Laboratories, Inc.
• Cell Signaling Technology, Inc.
• Bio SB
• Agilent Technologies, Inc.
• Abcam Limited

Report Scope:

In this report, the Global Immunohistochemistry Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Immunohistochemistry Market, By Product:

• Antibodies
• Equipment
• Reagents
• Kits

Immunohistochemistry Market, By Application:

• Diagnostics
• Cancer
• Infectious Diseases
• Cardiovascular Diseases
• Autoimmune Diseases
• Diabetes Mellitus
• Nephrological Diseases
• Research

Immunohistochemistry Market, By End User:

• Hospitals & Diagnostic Laboratories
• Research Institutes
• Others

Immunohistochemistry Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Immunohistochemistry Market.

Available Customizations:

Global Immunohistochemistry market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Immunohistochemistry Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Antibodies, Equipment, Reagents, Kits)
  • 5.2.2. By Application (Diagnostics, Cancer, Infectious Diseases, Cardiovascular Diseases, Autoimmune Diseases, Diabetes Mellitus, Nephrological Diseases, Research)
  • 5.2.3. By End User (Hospitals & Diagnostic Laboratories, Research Institutes, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Immunohistochemistry Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Immunohistochemistry Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Immunohistochemistry Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Immunohistochemistry Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Immunohistochemistry Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Immunohistochemistry Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. United Kingdom Immunohistochemistry Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. Italy Immunohistochemistry Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. France Immunohistochemistry Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Immunohistochemistry Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia-Pacific Immunohistochemistry Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Immunohistochemistry Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Immunohistochemistry Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Immunohistochemistry Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Immunohistochemistry Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Immunohistochemistry Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. South America Immunohistochemistry Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Immunohistochemistry Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Immunohistochemistry Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Immunohistochemistry Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. Middle East and Africa Immunohistochemistry Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Immunohistochemistry Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Immunohistochemistry Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Immunohistochemistry Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Immunohistochemistry Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Thermo Fisher Scientific Inc
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. F. Hoffmann-La Roche Ltd.
• 14.3. Merck KGaA
• 14.4. Danaher Corporation
• 14.5. PerkinElmer U.S. LLC
• 14.6. Bio-Rad Laboratories, Inc.
• 14.7. Cell Signaling Technology, Inc.
• 14.8. Bio SB
• 14.9. Agilent Technologies, Inc.
• 14.10.Abcam Limited

15. Strategic Recommendations

16. About Us & Disclaimer